Do Verve's gene edits pass down to patients' children? The FDA wants to know
By Nick Paul Taylor,
Fierce Biotech
| 12. 05. 2022
The FDA has set out its reasons for putting Verve Therapeutics’ high cholesterol gene editing therapy on hold. Officials want additional data to allay concerns that patients could pass on the edited genes to their children before they lift the clinical hold.
Last month, the FDA put Verve’s application on hold and vowed to send an official letter setting out its questions within 30 days. Verve now has the letter—and knows what needs to be done to get the clinical trial of its PCSK9-deactivating drug candidate VERVE-101 off the ground.
The FDA has asked for more preclinical data on potency differences between human and non-human cells, the risks of germline editing and off-target analyses in non-hepatocyte cell types. Officials also want Verve to share data from the heart-1 trial, which continues to enroll patients in New Zealand and the U.K., and to tweak the protocol to mitigate the risks of the therapy.
Specifically, the FDA has asked Verve to incorporate additional contraceptive measures and to increase the length of the staggering interval between dosing of participants. Verve plans to submit... see more
Related Articles
Gene therapy has been the next big thing in medicine for decades. Until recent years, the results were underwhelming. Now there are promising developments and real successes, but significant questions remain: Is it safe enough? How many people might benefit, and under what conditions? And, crucially, how much will gene therapies cost and who will pay?
It has been more than 50 years since gene therapy was formally proposed; more than 40 years since the first scandal; more than 30...
By Manuel Ansede, El País | 01.15.2023
The gene editing techniques that have revolutionized medicine since 2016 could also be used to treat common heart diseases, the number one cause of death in humans, according to a study published recently by one of the world’s leading scientists, ...
By CGS Staff
| 01.14.2023
Photo by Isabela Kronemberger on Unsplash
Throughout 2022, CGS worked to deepen and expand collaborations with advocates and scholars concerned about the social justice implications of a range of human biotechnologies, with a major focus on the alarming prospect of using genome editing in human reproduction. We also organized and sponsored public events; curated, analyzed, and commented on news related to human genetics and assisted reproduction, both in media outlets and in our own newsletter and social media; and conducted...
By Emily Sohn, Nature | 01.09.2023
Each day, around 350 people in the United States die from lung cancer. Many of those deaths could be prevented by screening with low-dose computed tomography (CT) scans. But scanning millions of people would produce millions of images, and there...
